Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

FDA Approval Sought for Fruquintinib in Refractory Metastatic Colorectal Cancer

March 31st 2023

A new drug application seeking the approval of fruquintinib for use in the treatment of patients with refractory metastatic colorectal cancer has been submitted to the FDA.

Encouraging Data Pave the Way for New Standards in CRC

March 29th 2023

As the development of systemic treatments for metastatic colorectal cancer move toward precision therapy, guidelines have adjusted to integrate decisions based on molecular drivers.

Severity of Patient-Reported Symptom Burden Remains Low and Stable After Adjuvant Systemic Treatment in CRC

March 29th 2023

Although some patients with stage II/III colorectal cancer were at an increased risk of severe symptoms and deterioration over time, patient-reported symptoms showed that those with newly diagnosed disease generally reported a low symptom burden that remained stable or improved after receiving adjuvant systemic therapy, according to a retrospective analysis.

Dr Muslimani on the Implications of the MOUNTAINEER Trial in HER2+ mCRC

March 27th 2023

Alaa Muslimani, MD, discusses the unmet needs for patients with HER2-positve metastatic colorectal cancer and highlights the implications of the phase 2 MOUNTAINEER trial in this patient population.

Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials

March 27th 2023

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

Combination IO/TKI Strategies in Metastatic Colorectal Cancer

March 27th 2023

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

Clinical Trials in Metastatic Colorectal Cancer: Combination IO Therapy

March 20th 2023

A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.

Overview of Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer

March 20th 2023

Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.

Dr. Fountzilas on Molecular Characterization in mCRC

March 16th 2023

Christos Fountzilas, MD, FACP, discusses findings from a study of molecular characterization in patients with colorectal cancer treated with cetuximab, an EGFR inhibitor, and pembrolizumab, a PD-1 inhibitor.

Other Combination Strategies in BRAF-Mutated Metastatic Colorectal Cancer

March 13th 2023

Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.

Combination Therapy in BRAF-Mutated mCRC: The BREAKWATER Trial

March 13th 2023

Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.

STELLAR-303 Aims to Carve Out Space for XL092 in mCRC Treatment Paradigm

March 9th 2023

Despite incremental advances in the treatment landscape of metastatic colorectal cancer, patients with the disease still face a poor prognosis.

Dr. Foote on the Quest to Determine Optimal Sequencing in Late-line mCRC

March 6th 2023

Micheal Foote, MD, discusses the quest to determine optimal sequencing of current therapeutics in the third-line setting and beyond for metastatic colorectal cancer.

Combination Therapy in BRAF-Mutated mCRC: The BEACON CRC Trial

March 6th 2023

Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.

Importance of Identifying HER2 Status in Metastatic Colorectal Cancer

March 6th 2023

Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.

Role of Tucatinib in HER2+ mCRC

February 27th 2023

Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.

HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates

February 27th 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

Triplet Regimen for Microsatellite Stable, BRAF V600E–Mutant mCRC Aims to Build Upon SOC

February 27th 2023

Because a positive correlation has been shown between expression of PD-L1 and BRAF V600E mutations in CRC, several combination therapies with checkpoint inhibitors and targeted agents are currently being explored.

Bevacizumab Plus TAS-102 Elicits Survival Improvements in Third-line mCRC

February 24th 2023

Bevacizumab plus trifluridine/tipiracil demonstrated improved overall survival and progression-free survival vs TAS-102 alone as third-line treatment for patients with refractory metastatic colorectal cancer.

Trastuzumab Deruxtecan in HER2+ mCRC

February 20th 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.